BACKGROUND: Advanced cholangiocarcinoma carries a poor prognosis, and no standard treatment exists beyond first-line gemcitabine/platinum-based chemotherapy. A single-arm, phase 2 and biomarker study of cabozantinib, a multikinase inhibitor with potent activity against vascular endothelial growth factor receptor 2 (VEGFR2) and MET, was performed for patients with advanced refractory cholangiocarcinoma. METHODS: Previously treated patients with unresectable or metastatic cholangiocarcinoma received cabozantinib (60 mg orally and daily on a continuous schedule). The primary endpoint was progression-free survival (PFS). Tumor MET expression and plasma biomarkers were evaluated. RESULTS: The study enrolled 19 patients with cholangiocarcinoma (female, 68%; median age, 67 years; intrahepatic vs extrahepatic, 84% vs 16%). The median PFS was 1.8 months (95% confidence interval, 1.6-5.4 months), and the median overall survival (OS) was 5.2 months (95% confidence interval, 2.7-10.5 months). Grade 3/4 adverse events occurred in 89% of the patients and included neutropenia (5%), hyperbilirubinemia (5%), epistaxis (5%), bowel perforation (5%), enterocutaneous fistulas (5%), and hypertension (11%). One patient with 3 1 MET expression in the tumor stayed on treatment for 278 days, but the MET expression did not correlate with the outcomes in the overall study population. Plasma vascular endothelial growth factor, placental growth factor, and stromal cell-derived factor 1a increased and soluble VEGFR2 and angiopoietin 2 decreased after treatment (all P values < .01). Plasma tissue inhibitor of matrix metalloproteinase 1 was inversely correlated with PFS, and soluble MET (sMET) and interleukin 6 were inversely correlated with OS. CONCLUSIONS: In unselected patients with cholangiocarcinoma, cabozantinib demonstrated limited activity and significant toxicity. In the first clinical trial to assess the role of MET inhibition in cholangiocarcinoma, 1 patient with a MET-high tumor had a prolonged benefit from treatment. Baseline plasma soluble MET was associated with OS. Any further development of this drug in cholangiocarcinoma should include a dose reduction and a biomarker-driven approach.
INTRODUCTION
Cholangiocarcinoma is a rare malignancy of the intrahepatic and extrahepatic bile ducts with a poor prognosis. Recent data have shown that intrahepatic cholangiocarcinoma (ICC) is rising in incidence globally. 1 Although surgery can be curative if the tumor is detected early, recurrence rates are as high as 70% to 75%, and 5-year overall survival (OS) rates are as low as 5% to 10%. 1 The standard first-line treatment for unresectable/advanced disease consists of gemcitabine and platinum chemotherapy and offers a median OS of approximately 1 year. 2 No standard therapy exists beyond the first line, and no targeted therapies are approved for this disease. The use of other regimens in the second line, such as fluoropyrimidine-or taxane-based regimens, is associated with a median progression-free survival (PFS) of 2.8 months and a median OS of 7.5 months. 3 Vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor (HGF) receptor MET signaling are often upregulated in cholangiocarcinoma and promote carcinogenesis by increasing angiogenesis and invasion. Vascular endothelial growth factor (VEGF) is expressed in approximately 50% of ICCs and in 32% to 59% of extrahepatic cholangiocarcinomas (ECCs), 4, 5 and it is associated with metastasis and with recurrence and poor OS in biliary tract cancer. 5, 6 Similarly, MET is expressed in 20% to 58% of ICCs and in 0% to 68% of ECCs. [7] [8] [9] [10] Moreover, MET overexpression is seen in 12% of ICCs and in 16% of ECCs and correlates with decreased 5-year OS. 9 Cabozantinib is an orally bioavailable multikinase inhibitor whose targets include VEGFR2 (half maximal inhibitory concentration (IC50), 0.035 nM) and MET (IC50, 1.3 nM). Dual inhibition of these 2 receptors has been shown to have synergistic antitumor effects due to the intricate crosstalk between the VEGF/VEGFR2 and HGF/MET pathways. 11 For example, over time, VEGFR2 inhibition may cause an increase in tumor hypoxia, which can upregulate MET, enhance cancer cell invasion, and promote treatment resistance. 12 In the first clinical trial to address the role of MET inhibition in cholangiocarcinoma, we evaluated cabozantinib in a phase 2 study of patients with advanced refractory cholangiocarcinoma. The primary objective of the study was to evaluate the PFS of these patients on cabozantinib (60 mg orally and daily on a continuous schedule). The correlative studies included an evaluation of tissue MET expression and plasma molecules as potential biomarkers of a response to cabozantinib.
MATERIALS AND METHODS

Study Population
Patients with histologically proven and measurable unresectable or metastatic cholangiocarcinoma were eligible. Other inclusion criteria included the following: progressive disease after 1 or 2 prior lines of systemic therapy for advanced cholangiocarcinoma; age 18 years; Eastern Cooperative Oncology Group performance status 1; life expectancy 3 months; white blood cell count 1500/lL and platelet count 100,000/lL; hemoglobin level 9 g/ dL; serum creatinine level 1.5 mg/dL or glomerular filtration rate 60 mL/min/1.73 m 2 ; total bilirubin level < 2 times the upper limit of normal (ULN) and aspartate aminotransferase and alanine aminotransferase levels 5 times the ULN; lipase level < 2.0 times the ULN; serum phosphorus, calcium, magnesium, and potassium levels lower limit of normal; albumin level 2.8 g/dL; prothrombin time/partial thromboplastin time 1.5 times the ULN; and urine protein/creatinine ratio 1.
Key exclusion criteria included the following: prior treatment with cabozantinib or other VEGFR-targeted therapies; gallbladder carcinoma or periampullary tumors; chemotherapy within the previous 4 weeks; radiation to the thorax, abdomen, or pelvis in the previous 3 months or to bone or brain metastases in the previous 14 days; sustained blood pressure > 140 mm Hg (systolic) or > 90 mm Hg (diastolic) despite optimal antihypertensive treatment within the previous 7 days; QTc > 500 milliseconds; class III or IV congestive heart failure; prior history of pulmonary embolism or deep venous thrombosis; unstable angina, clinically significant cardiac arrhythmia, stroke, myocardial infarction, thromboembolic event requiring therapeutic anticoagulation, venous filter, or clinically significant gastrointestinal bleeding within the previous 6 months; gastrointestinal disorders associated with a high risk of perforation or fistula formation; severely impaired lung function or history of interstitial lung disease; history of hepatic encephalopathy; active brain or epidural metastases; history of organ transplantation; major surgery within the previous 3 months or minor surgery within the previous month (biliary stenting was not considered minor surgery and did not require a delay); concomitant use of therapeutic anticoagulation or strong cytochrome P450 3A4 inducers or inhibitors; treatment with another investigational agent within the previous 28 days; uncompensated hypothyroidism; concurrent malignancy; and pregnancy or lactation. All patients provided written informed consent before study participation. The protocol was approved by the Partners institutional review board.
Study Design
In this single-arm, phase 2 study, patients received cabozantinib (60 mg orally and daily on a continuous schedule) for repeated 28-day cycles. Dose reductions were permitted down to 2 dose levels: 40 and 20 mg orally and daily. The primary endpoint was PFS. Secondary endpoints included the objective response rate, OS, safety, and tolerability as well as a preplanned post hoc analysis of the PFS, objective response rate, and OS by tumor MET expression. Plasma biomarkers were assessed as potential biomarkers of responses.
Patients were evaluated for a response serologically with carbohydrate antigen 19-9 levels and radiographically with computed tomography or magnetic resonance imaging every 8 weeks. A response was determined by an independent radiologic review using version 1.1 of the Response Evaluation Criteria in Solid Tumors (RECIST), 13 and patients continued treatment until disease progression, unacceptable toxicity, or the withdrawal of consent. Patients were monitored for safety weekly in cycle 1, every other week in cycle 2, and monthly thereafter. Safety evaluations included vital signs, a physical examination, a performance status evaluation, complete blood counts, blood chemistries, coagulation studies, thyroid function tests, Original Article urinalyses, and electrocardiograms. Adverse events were assessed according to the National Cancer Institute's Common Toxicity Criteria for Adverse Events (version 4.0). Safety data were monitored on an ongoing basis by an independent data and safety monitoring committee.
Correlative Studies
Plasma biomarkers
Exploratory analyses of potential plasma biomarkers of cabozantinib were performed via the measurement of proteins in the plasma at the baseline (1 day before the first dose of cabozantinib) and their changes after 1 (range, 3-6 weeks) and 2 weeks of treatment (range, 13-18 weeks) to accommodate weekends and holidays. A plasma analysis was performed for a panel of circulating proangiogenic and proinflammatory biomarkers: VEGF, placental growth factor (PlGF), soluble vascular endothelial growth factor receptor 1 (sVEGFR1)/FLT-1, basic fibroblast growth factor (bFGF), VEGF-C, VEGF-D, sTIE-2, interleukin-1b (IL-1b), IL-2, IL-4, IL-6, IL-8, IL-10, IL12p70, interferon-c (IFN-c), and tumor necrosis factor a (TNF-a) with multiplex protein array plates from MesoScale Discovery (Gaithersburg, Md); HGF, sVEGFR2, angiopoietin 1 (Ang-1), Ang-2, tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), carbonic anhydrase IX (CAIX), free insulin-like growth factor 1 (IGF-1), and stromal cell-derived factor 1a (SDF1a) from R&D Systems (Minneapolis, Minn); and soluble MET (sMET) from Life Technologies/Invitrogen (Carlsbad, Calif). All samples were run in duplicate.
Tissue biomarkers
An immunohistochemical evaluation of total MET was performed with an anti-total MET rabbit monoclonal primary antibody (SP44; Ventana Medical Systems, Tucson, Ariz). The active fraction of the MET protein was determined with an anti-phospho-MET (Tyr1349) rabbit monoclonal antibody (EP2367Y) from Millipore (Billerica, Mass). The immunohistochemical analysis was performed on the Ventana BenchMark XT platform according to standard protocols, and samples were processed in a batch to minimize interrun variability. The immunohistochemistry scoring was performed by a trained gastrointestinal pathologist (V.N.). As defined in the OAM4558g MetMAb phase 2 study, 14 the scoring criteria for MET positivity were 50% of tumor cells being positive for target immunostaining with a moderate or strong intensity (21) .
Statistical Methods
The sample size was based on a Simon 2-stage design with 80% power to reject the null hypothesis of a 16-week PFS rate of 36% if the true PFS rate with cabozantinib was 54%. With these criteria, the target accrual for stage I was 20 patients, and at least 9 patients needed to be progression-free at 16 weeks before the second stage could proceed. If this criterion was met, an additional 24 patients were to be enrolled in stage II. At least 20 of the 44 patients enrolled in stages I and II needed to be progression-free at 16 weeks to warrant further development of this agent in this setting.
All patients who received at least 1 dose of cabozantinib were included for the safety and efficacy analysis. PFS was defined as the time from trial registration to evidence of radiographic progression (as defined by RECIST criteria) or death from any cause without evidence of disease progression, whichever occurred first. OS was defined as the time from trial registration to death from any cause. Cases with incomplete follow-up or without adequate disease evaluations were censored at the date on which they were last documented to be progression-free. KaplanMeier estimates of the median PFS and OS were calculated along with their corresponding 95% confidence intervals. For biomarker changes over time, we used the Wilcoxon signed rank test. Given the exploratory nature of these analyses, we did not correct for multiple comparisons. A Cox proportional hazards regression model was used to assess the effects of cabozantinib and biomarkers on PFS and OS. The point estimate in the Cox regression model with a 95% confidence interval is presented. All analyses were performed with SAS 9.4 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
Between October 2013 and June 2014, 19 patients were registered and received at least 1 dose of cabozantinib. The median age of the patients was 67 years, and most patients had ICC (84%). Fifty-three percent of the patients had progressed on only 1 previous line of therapy, and 47% had progressed on 2 previous lines (see Table 1 ).
Patients received a median of 2 cycles (range, 1-10 cycles) of treatment. Dose reductions to 40 and 20 mg were required for 11 patients (57.9%) and 1 patient (5.3%), respectively; all were due to toxicity. The median duration on therapy was 57 days (range, 8-278 days). At the time of the analysis, all 19 patients had discontinued cabozantinib treatment: 11 because of radiological progression, 5 because of clinical progression with stable disease according to the RECIST criteria, 2 because of toxicities, and 1 because of death. The toxicities that led to discontinuation were a grade 3 enterocutaneous fistula and a grade 3 gastrointestinal perforation. The patient who had an enterocutaneous fistula healed after a treatment break and went on to subsequent treatment. The patient who had a gastrointestinal perforation passed away 3 weeks later. The death that occurred while a subject was in the study was recorded within 30 days of the study treatment; the patient was admitted for abdominal pain in the setting of progression of peritoneal metastases and died 3 days later. After withdrawal for progression, 6 of 16 patients (38%) received further systemic therapy, including 5-fluorouracil/leucovorin (n 5 1), 5-fluorouracil/leucovorin/oxaliplatin (n 5 2), erlotinib (n 5 1), programmed death ligand 1 inhibitor MPDL280A in a clinical trial (n 5 1), and stem cell kinase inhibitor BBI503 in a clinical trial (n 5 1).
Safety
The most common drug-related adverse events of any grade were fatigue (74%), elevated aspartate aminotransferase (74%), and thrombocytopenia (63%), and most of these were grade 1 or 2 (see Table 2 ). Toxicities potentially related to VEGF inhibition and attributed to therapy included fatigue (74%), hypertension (37%), diarrhea (26%), mucositis (37%), palmar plantar erythrodysesthesia (21%), and minor bleeding (5%). Grade 3 and 4 adverse events occurred in 89% of the patients and included but were not limited to neutropenia (5%), hyperbilirubinemia (5%), epistaxis (5%), bowel perforation (5%), enterocutaneous fistula (5%), and hypertension (11%; see Table 3 ). No patients experienced liver failure, and no treatment-related deaths occurred. The aforementioned death was attributed by the investigator to complications of disease progression.
Efficacy
After 12 patients had failed to be progression-free at 16 weeks, the study was terminated because it was determined that the criterion for proceeding to stage 2 could not be met. With a median follow-up of 5.2 months, the median PFS was 1.8 months (95% confidence interval, 1.6-5.4 months), and the median OS was 5.2 months (95% confidence interval, 2.7-10.5 months). No objective responses were seen. Five patients (26%) had stable disease at 16 weeks.
Correlative Studies
Plasma VEGF, PlGF, VEGF-D, and SDF1a levels increased and Ang-2, TIMP-1, and TNF-a levels decreased at both time points (1 and 2 weeks) after treatment (Table  4) . Plasma IL-10 and IFN-c levels transiently decreased during week 1, and IGF-1 and sTIE-2 levels increased and sVEGFR2, HGF, and IL-8 levels decreased only after 2 weeks of treatment (all P values < .05). Notably, previous pharmacokinetic studies have shown that a steady state is achieved only after 2 weeks of daily dosing of cabozantinib. 15, 16 There were no significant changes detected in plasma sMET, CAIX, sVEGFR1, VEGF-C, Ang-1, bFGF, IL-1b, IL-2, IL-6, or IL-12 p70 at these time points. Among the baseline biomarkers, a low plasma TIMP-1 level was associated with longer PFS (P 5 .029), and a low IL-6 level (P 5 .021) and a high sMET level (P 5 .0027) were correlated with longer OS. Tumor MET overexpression (estimated as 2 1 or 3 1 by immunohistochemistry) was seen in 4 of the 10 patients evaluated (see Fig. 1 ). The remainder of the patients (n 5 9) had insufficient tissue for testing. The patient with the longest disease control (9.2 months) had 3 1 tumor MET expression, but the MET expression status by immunohistochemistry did not correlate with PFS (P 5 .38) or OS (P 5 .17) in the 10 patients evaluated.
DISCUSSION
The current study is the first clinical trial to evaluate the role of MET inhibition in patients with cholangiocarcinoma. As an oral, once daily multikinase inhibitor, cabozantinib targets VEGFR2, MET, RET, KIT, AXL, FLT3, and TIE-2. In this trial, cabozantinib demonstrated limited clinical activity in an unselected population of patients with advanced refractory cholangiocarcinoma. However, 1 patient with 3 1 MET overexpression in the tumor stayed on the treatment for 278 days. This observation suggests that any path forward for this agent in cholangiocarcinoma would involve a biomarker-driven approach. Our study included exploratory biomarker studies using a panel of plasma and tissue biomarkers to examine cabozantinib's impact on proangiogenic and immune pathways as well as the HGF/MET pathway in cholangiocarcinoma.
The correlative studies confirmed pharmacodynamic biomarker changes consistent with antiangiogenic effects of cabozantinib. The treatment was associated with significant increases in VEGF, PlGF, and SDF1a and decreases in Ang-2 and sVEGFR2, as seen with cabozantinib and other VEGFR2 kinase inhibitors in liver cancer and other solid tumors. [17] [18] [19] [20] [21] In addition and in agreement with data from breast cancer patients, cabozantinib treatment was associated with an increase in plasma VEGF-D, IGF-1, and sTIE-2 levels. As also seen in breast cancer, cabozantinib treatment led to a decrease in plasma HGF and TIMP-1, both of which are associated with stellate cell activation and fibrosis, as well as a decrease in the cytokines IFN-c, TNF-a, IL-8, and IL-10. 17 These data indicate that the agent also has potential antifibrotic and anti-inflammatory activity in cholangiocarcinoma. Further to this point, plasma TIMP-1 and IL-6, biomarkers known to be associated with liver fibrosis and immunosuppression in cholangiocarcinoma, [22] [23] [24] [25] [26] [27] were associated in this study with PFS and OS, respectively. Plasma TIMP-1 is an established biomarker of liver fibrogenesis but has not been yet used as a biomarker of tumor fibrosis in a highly desmoplastic disease such as cholangiocarcinoma. Although the exact effects of cabozantinib on the cholangiocarcinoma microenvironment and systemic immunity remain to be established, the drug exerts intriguing changes on the immune system, 17, 28, 29 and these mechanisms may be relevant for designing future combinations with other agents such as immunotherapy. However, these biomarker analyses were not adjusted for multiple comparisons and, therefore, are hypothesisgenerating only.
Despite the intriguing response seen in the patient whose tumor had MET overexpression, in the overall study population, high MET expression in tumor tissue did not appear to correlate with cabozantinib activity. This lack of correlation was based on a limited number of cases and a lack of pretreatment biopsies, but this finding is consistent with the data for renal cell carcinoma and breast cancer. 17, 30 High pretreatment plasma sMET levels, however, did correlate with longer OS in the overall study population, and this result is also consistent with the cabozantinib experience in advanced triple-negative breast cancer, for which higher sMET levels have been significantly associated with better outcomes. 17 Although hypothesis-generating in nature, these results warrant further evaluations of tissue MET and plasma sMET in larger studies of patients receiving cabozantinib.
Despite close monitoring, a high rate of grade 3 or higher toxicities was observed at daily dosing of 60 mg. The majority of the grade 3 and 4 toxicities (72%) were laboratory abnormalities, none led to drug discontinuation, and many were in patients who had abnormal baseline liver function tests or blood counts. Although some patients with ICC can have underlying cirrhosis, 31-33 only 1 patient in this trial had a history of cirrhosis according to a review of the imaging and clinical histories of all patients. The rate of dose reductions (63%) was similar to the rate seen in a phase 3 trial in advanced renal cell carcinoma (62%) 30 but was higher than the rate seen in a phase 3 trial in metastatic castrate-resistant prostate cancer (33%) 34 and a phase 2 trial in breast cancer (34%), 17 all of which evaluated daily 60-mg dosing. Patients with advanced refractory cholangiocarcinoma may be more sensitive to drug doses tolerated by other solid-tumor patient populations; therefore, close monitoring remains critical for these patients in early-phase clinical trials.
This study has limitations, including its single-arm design and small sample size. In addition, tissue for the biomarker analysis was available for only 54% of the patients. Tissue was prioritized for clinical testing, including tumor genetic profiling, so minimal or no tissue was available for correlative research studies for some patients. Because the majority of patients with cholangiocarcinoma are diagnosed by fine-needle aspiration or core liver biopsy, the paucity of tissue is a common occurrence that hinders tissue biomarker discovery in this disease. If additional tissue had been available, an analysis of VEGF expression and MET amplification could also have been conducted, although neither of these has consistently been Abbreviations: Ang, angiopoietin; bFGF, basic fibroblast growth factor; CAIX, carbonic anhydrase IX; HGF, hepatocyte growth factor; IFN-g, interferon-g; IGF-1, free insulin-like growth factor 1; IL, interleukin; IQR, interquartile range; N/A, not applicable; PlGF, placental growth factor; SDF1a, stromal cell-derived factor 1a; sMET, soluble MET; sVEGFR, soluble vascular endothelial growth factor receptor; sTIE-2, soluble TEK receptor tyrosine kinase; TIMP-1, tissue inhibitor of matrix metalloproteinase 1; TNF-a, tumor necrosis factor a; VEGF, vascular endothelial growth factor. Medians and IQRs for IL-1b and IL-4 were not tabulated because the majority had median values under the detectable threshold. For all other biomarkers, data are reported from n 5 16-19 patients, with the exception of CAIX ( n5 9-10 patients).
These P values were obtained with the Wilcoxon signed rank test.
found to predict a response to antiangiogenic drugs or MET inhibitors. Because of the intriguing preclinical data and clinical correlative results suggesting immunomodulatory effects of cabozantinib, future studies of cabozantinib in cholangiocarcinoma may include combinations with chemotherapy or immune checkpoint blockers. A randomized phase 2 study of gemcitabine and cisplatin with and without the potent type II adenosine triphosphate-competitive MET kinase inhibitor merestinib, which also inhibits at least 13 other receptor tyrosine kinases, is currently ongoing in patients with advanced biliary tract cancer (NCT02711553). A trial of cabozantinib plus nivolumab alone or with ipilimumab is currently underway in patients with metastatic genitourinary cancers (NCT02496208) and may lead to development in other solid tumors if it is tolerable and effective. Ultimately, a strong focus on correlative studies in these trials and others will hopefully pave the path forward for selecting subpopulations likely to benefit from a strategy of MET inhibition in cholangiocarcinoma.
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